Navigation Links
Innocoll Enters Partnership with Merus Labs in Canada for the Distribution of CollaGUARD
Date:11/15/2011

ASHBURN, Va., Nov. 15, 2011 /PRNewswire/ -- Innocoll Inc. announced it has entered into a License and Distribution Agreement with Merus Labs Inc. in Canada for CollaGUARD surgical adhesion barrier for the prevention of postoperative adhesions following abdominal and pelvic surgery.  

Dr. Michael Myers, President and CEO stated, "We are pleased to announce the expansion of our partnership with Merus to include CollaGUARD and we look forward to the successful launch of the product in Canada."  

Ali Moghaddam, Vice President at Merus Labs added, "Adhesions occur after most surgical procedures, and are of major clinical, social and economic concern. The addition of CollaGUARD to our portfolio means that millions of patients at risk of adhesion will have a clinically proven superior solution. We look forward applying for Health Canada approval and working with our key opinion leaders to launch this important product. CollGUARD will add significant scale to our women's health portfolio."

About CollaGUARD®
CollaGUARD is a transparent bioresorbable film of 100% type I collagen developed using Innocoll's proprietary CollaFilm technology. It is approved in Europe for the prevention of postoperative adhesions in patients undergoing abdominopelvic laparotomy or laparoscopy.  When tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by more than six fold (< 0.001) and significantly reduced the extent and severity of adhesions (< 0.001).

CollaGUARD has been designed and engineered with a unique combination of features for optimal handling, ease-of-use, and antiadhesion performance. It is highly stable at room temperature and does not require any advanced preparation before use. The product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically. CollaGUARD is available in a wide variety of sizes up to 20 x 30 cm; it may be cut and sutured if required and therefore used efficiently across a broad range of surgeries.

About Postoperative Adhesions
Postoperative adhesions are abnormal fibrous connections that can form between any apposing internal organ and serous membrane as a natural consequence of abdominopelvic surgery. Adhesions occur in almost 95% of laparotomies and may lead to serious complications such as intestinal obstruction, secondary female infertility, and chronic abdominal or pelvic pain. More than 30% of patients who undergo open gynecologic or general surgery are readmitted within 10 years for disorders that are considered directly or potentially related to adhesions, with an average of 2 readmissions per patient. In the United States, there are approximately 350,000 hospitalizations annually for adhesiolysis following gynecologic or abdominal surgery, which account for almost 1 million inpatient days at a cost of $2.3 billion. Even for patients without complications, adhesions originating from a previous surgery can present significant surgical challenges and additional morbidity risks in subsequent operations.

About Merus Labs Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm, DermaSil™, CollaPress and Liquicoll®. Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, CollaGUARD, Collieva®, CollaCare®, Collexa®, Zorpreva™, and LidoColl®.

Other products in clinical and regulatory development include: CollaRx Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and Xaracoll in phase 2b for the management of post-operative pain. For more information, please visit www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD
2. Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier
3. Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products
4. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
5. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
6. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
7. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
11. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/15/2017)... , July 15, 2017 Enterin Inc., a ... to treat Parkinson,s disease (PD), today announced the completion of ... new investors New Ventures III, as well as the participation ... are absolutely thrilled to have the support of New Ventures ... our investors as validation of the potential of our platform ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/13/2017)... Calif. , July 13, 2017 RK Logistics ... Board of Pharmacy certification for its Fremont, CA ... support solutions in the Tri-Valley and San Jose ... City of Fremont , with its Fremont ... Group to provide such a powerful resource to the hundreds ...
Breaking Medicine Technology:
(Date:7/25/2017)... , ... July 25, 2017 , ... ... assistance and finance management services to communities across North Carolina, is launching a ... Network to raise community support for the ongoing fight against bladder cancer. , ...
(Date:7/25/2017)... ... ... Facing medical needs with a newborn boy this spring, Crowley Maritime Corp. ... employees that is uncommon in American business: 12 weeks of fully paid parental leave. ... as new parents. It keeps our family life more stable. I can be there ...
(Date:7/24/2017)... ... ... Cheerag D. Upadhyaya , M.D., M.Sc., FAANS has been appointed surgical ... of Saint Luke’s Health System . Dr. Upadhyaya has served in the role ... joins Stanley P. Fisher, M.D., who has served as medical co-director of ...
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm fire in ... and threatened numerous homes and businesses nearby, causing some 700 individuals to be ... Angeles Area consulting firm Fire Protection Group, Inc. notes that the report is ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin care ... one of the leading causes of long term skin conditions, including cancer. ...
Breaking Medicine News(10 mins):